The demand to develop and deliver new doses has never been more intense - and one country is leading the way in the challenge ...

GSK’s long-acting asthma treatment has been shown to halve the number of attacks in a pair of phase 3 trials, supporting the Big Pharma’s push toward approval despite falling short on some ...

Sept 11 (Reuters) - British drugmaker GSK (GSK.L), opens new tab said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main goal of a mid-stage trial ...

GSK has shifted towards a global marketing model influenced by a Netflix-style approach that aims to match content to the person receiving it. Richard Staines heard about this new strategy at the ...

As part of the agreement, GSK, Sanofi, and CSL will produce extra bulk vaccine components tailored to the circulating strains of avian influenza. Also Read: Medicare Drug Price Negotiation Program ...

GSK has demonstrated robust sales growth, with a 13% increase to GBP 7.9 billion and a core operating profit up by 21% to GBP 2.5 billion, as noted by CEO Emma Walmsley in the latest earnings call.

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

iTeos Therapeutics (NASDAQ:ITOS) announced Saturday that its experimental cancer doublet therapy developed with GSK (NYSE:GSK) outperformed the British drugmaker’s FDA-approved anti-PD-1 therapy ...

GSK Plc’s experimental vaccine for herpes failed in an early-stage trial, halting an effort to bring the first shot for the condition to market. While there were no safety concerns, the trial ...

However, the earlier flops shook TIGIT players, with GSK and iTeos assessing “how best to proceed with additional clinical development” of their rival asset after a phase 3 Roche flop in 2022 ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50. The company’s shares closed yesterday at p1,497. ...